KCNH1 and cancer: We hope that the molecular mechanism of imipramine inhibition uncovered in our study will facilitate the development of EAG1 channel-specific small molecule inhibitors that bind to their intracellular PAS domains and can be used for the treatment of cancer and neurological disorders associated with defects in EAG1 channel function.